<i>ROS1-1</i>

Pal, Prodipto; Khan, Zanobia

doi:10.1136/jclinpath-2016-204244

Cited by 16 publications

(7 citation statements)

References 81 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For optimal clinical efficacy of TRK inhibitors, an effective diagnostic strategy to detect NTRK gene fusions in tumour samples is essential to guide treatment selection. Approaches that may be used to directly or indirectly detect the presence of a gene fusion in clinical tissue samples51 include immunohistochemistry (IHC), fluorescence in situ hybridisation (FISH), reverse transcriptase polymerase chain reaction (RT-PCR) and next-generation sequencing (NGS) using DNA or RNA (table 2). 10 18 32 34 52–58…”

Section: Testing Methods For Trk Fusion Cancersmentioning

confidence: 99%

Testing algorithm for identification of patients with TRK fusion cancer

2019

View full text Add to dashboard Cite

The neurotrophic tyrosine receptor kinase (NTRK) gene family encodes three tropomyosin receptor kinases (TRKA, TRKB, TRKC) that contribute to central and peripheral nervous system development and function. NTRK gene fusions are oncogenic drivers of various adult and paediatric tumours. Several methods have been used to detect NTRK gene fusions including immunohistochemistry, fluorescence in situ hybridisation, reverse transcriptase polymerase chain reaction, and DNA- or RNA-based next-generation sequencing. For patients with TRK fusion cancer, TRK inhibition is an important therapeutic target. Following the FDA approval of the selective TRK inhibitor, larotrectinib, as well as the ongoing development of multi-kinase inhibitors with activity in TRK fusion cancer, testing for NTRK gene fusions should become part of the standard diagnostic process. In this review we discuss the biology of NTRK gene fusions, and we present a testing algorithm to aid detection of these gene fusions in clinical practice and guide treatment decisions.

show abstract

Section: Testing Methods For Trk Fusion Cancersmentioning

confidence: 99%

Testing algorithm for identification of patients with TRK fusion cancer

2019

View full text Add to dashboard Cite

show abstract

“…Some molecular alterations have gained attention in the last years, specially ROS1 fusions, present in 2–3% of the lung adenocarcinomas, as well as in cholangio, gastric and colonic carcinomas [ 179 ]. They are present in spitzoid neoplasms, glioblastoma multiforme and inflammatory myofibroblastic tumors, too.…”

Section: Tyrosine Kinase Receptor Inhibitors Developed For Cancer mentioning

confidence: 99%

Tyrosine Kinase Receptors in Oncology

Esteban-Villarrubia

Castillo

Pozas

et al. 2020

IJMS

View full text Add to dashboard Cite

Tyrosine kinase receptors (TKR) comprise more than 60 molecules that play an essential role in the molecular pathways, leading to cell survival and differentiation. Consequently, genetic alterations of TKRs may lead to tumorigenesis and, therefore, cancer development. The discovery and improvement of tyrosine kinase inhibitors (TKI) against TKRs have entailed an important step in the knowledge-expansion of tumor physiopathology as well as an improvement in the cancer treatment based on molecular alterations over many tumor types. The purpose of this review is to provide a comprehensive review of the different families of TKRs and their role in the expansion of tumor cells and how TKIs can stop these pathways to tumorigenesis, in combination or not with other therapies. The increasing growth of this landscape is driving us to strengthen the development of precision oncology with clinical trials based on molecular-based therapy over a histology-based one, with promising preliminary results.

show abstract

“…Only a few anti-ROS1 antibodies have been validated and recommended for use in daily routine practice [ 41 , 42 , 43 , 44 ]. The D4D6 (Cell Signaling Technology, Leiden, The Netherlands) clone is used by the majority of laboratories [ 38 ].…”

Section: The Therapeutic Targets Identified By Immunohistochemistrmentioning

confidence: 99%

Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

Hofman

Lassalle

Bence

et al. 2018

Cancers

View full text Add to dashboard Cite

The identification of certain genomic alterations (EGFR, ALK, ROS1, BRAF) or immunological markers (PD-L1) in tissues or cells has led to targeted treatment for patients presenting with late stage or metastatic lung cancer. These biomarkers can be detected by immunohistochemistry (IHC) and/or by molecular biology (MB) techniques. These approaches are often complementary but depending on, the quantity and quality of the biological material, the urgency to get the results, the access to technological platforms, the financial resources and the expertise of the team, the choice of the approach can be questioned. The possibility of detecting simultaneously several molecular targets, and of analyzing the degree of tumor mutation burden and of the micro-satellite instability, as well as the recent requirement to quantify the expression of PD-L1 in tumor cells, has led to case by case development of algorithms and international recommendations, which depend on the quality and quantity of biological samples. This review will highlight the different predictive biomarkers detected by IHC for treatment of lung cancer as well as the present advantages and limitations of this approach. A number of perspectives will be considered.

show abstract

ROS1-1

Cited by 16 publications

References 81 publications

Testing algorithm for identification of patients with TRK fusion cancer

Testing algorithm for identification of patients with TRK fusion cancer

Tyrosine Kinase Receptors in Oncology

Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

Contact Info

Product

Resources

About